Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 36 entries
Sorted by: Best Match Show Resources per page
New antiresorptive therapies for postmenopausal osteoporosis.

Journal of menopausal medicine

Choi HJ.
PMID: 26046031
J Menopausal Med. 2015 Apr;21(1):1-11. doi: 10.6118/jmm.2015.21.1.1. Epub 2015 Apr 27.

Osteoporosis is a systemic skeletal disease whose risk increases with age and it is common among postmenopausal women. Currently, almost all pharmacological agents for osteoporosis target the bone resorption component of bone remodeling activity. Current antiresorptive agents are effective,...

Cite
Choi HJ. New antiresorptive therapies for postmenopausal osteoporosis. J Menopausal Med. 2015;21(1):1-11doi: 10.6118/jmm.2015.21.1.1.
Choi, H. J. (2015). New antiresorptive therapies for postmenopausal osteoporosis. Journal of menopausal medicine, 21(1), 1-11. https://doi.org/10.6118/jmm.2015.21.1.1
Choi, Hee-Jeong. "New antiresorptive therapies for postmenopausal osteoporosis." Journal of menopausal medicine vol. 21,1 (2015): 1-11. doi: https://doi.org/10.6118/jmm.2015.21.1.1
Choi HJ. New antiresorptive therapies for postmenopausal osteoporosis. J Menopausal Med. 2015 Apr;21(1):1-11. doi: 10.6118/jmm.2015.21.1.1. Epub 2015 Apr 27. PMID: 26046031; PMCID: PMC4452807.
Copy Download .nbib Format: NLM
Comment on Sanfélix-Genovés et al.: Prevalence of osteoporotic fracture risk factors and antiosteoporotic treatments in the Valencia region, Spain. The baseline characteristics of the ESOSVAL cohort.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA

Pedrera-Zamorano JD, Lavado-Garcia JM, Moran JM.
PMID: 23052931
Osteoporos Int. 2013 Jun;24(6):1923-4. doi: 10.1007/s00198-012-2145-0. Epub 2012 Sep 29.

No abstract available.

Cite
Pedrera-Zamorano JD, Lavado-Garcia JM, Moran JM. Comment on Sanfélix-Genovés et al.: Prevalence of osteoporotic fracture risk factors and antiosteoporotic treatments in the Valencia region, Spain. The baseline characteristics of the ESOSVAL cohort. Osteoporos Int. 2012;24(6):1923-4doi: 10.1007/s00198-012-2145-0.
Pedrera-Zamorano, J. D., Lavado-Garcia, J. M., & Moran, J. M. (2013). Comment on Sanfélix-Genovés et al.: Prevalence of osteoporotic fracture risk factors and antiosteoporotic treatments in the Valencia region, Spain. The baseline characteristics of the ESOSVAL cohort. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 24(6), 1923-4. https://doi.org/10.1007/s00198-012-2145-0
Pedrera-Zamorano, J D, et al. "Comment on Sanfélix-Genovés et al.: Prevalence of osteoporotic fracture risk factors and antiosteoporotic treatments in the Valencia region, Spain. The baseline characteristics of the ESOSVAL cohort." Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA vol. 24,6 (2013): 1923-4. doi: https://doi.org/10.1007/s00198-012-2145-0
Pedrera-Zamorano JD, Lavado-Garcia JM, Moran JM. Comment on Sanfélix-Genovés et al.: Prevalence of osteoporotic fracture risk factors and antiosteoporotic treatments in the Valencia region, Spain. The baseline characteristics of the ESOSVAL cohort. Osteoporos Int. 2013 Jun;24(6):1923-4. doi: 10.1007/s00198-012-2145-0. Epub 2012 Sep 29. PMID: 23052931.
Copy Download .nbib Format: NLM
Bisphosphonate-associated osteonecrosis of the jaws.

Indian journal of dental research : official publication of Indian Society for Dental Research

Desai RS, Shetty SJ.
PMID: 23059592
Indian J Dent Res. 2012 May-Jun;23(3):432. doi: 10.4103/0970-9290.102251.

No abstract available.

Cite
Desai RS, Shetty SJ. Bisphosphonate-associated osteonecrosis of the jaws. Indian J Dent Res. 2012;23(3):432doi: 10.4103/0970-9290.102251.
Desai, R. S., & Shetty, S. J. (2012). Bisphosphonate-associated osteonecrosis of the jaws. Indian journal of dental research : official publication of Indian Society for Dental Research, 23(3), 432. https://doi.org/10.4103/0970-9290.102251
Desai, Rajiv S, and Shetty, Subraj J. "Bisphosphonate-associated osteonecrosis of the jaws." Indian journal of dental research : official publication of Indian Society for Dental Research vol. 23,3 (2012): 432. doi: https://doi.org/10.4103/0970-9290.102251
Desai RS, Shetty SJ. Bisphosphonate-associated osteonecrosis of the jaws. Indian J Dent Res. 2012 May-Jun;23(3):432. doi: 10.4103/0970-9290.102251. PMID: 23059592.
Copy Download .nbib Format: NLM
Autofluorescence-guided surgery for the treatment of medication-related osteonecrosis of the jaw (MRONJ): a retrospective single-center study.

Oral surgery, oral medicine, oral pathology and oral radiology

Otto S, Schnödt EM, Haidari S, Brunner TF, Aljohani S, Mosleh M, Ristow O, Troeltzsch M, Pautke C, Ehrenfeld M, Fliefel R.
PMID: 33309263
Oral Surg Oral Med Oral Pathol Oral Radiol. 2021 May;131(5):519-526. doi: 10.1016/j.oooo.2020.10.018. Epub 2020 Oct 26.

OBJECTIVE: Medication-related osteonecrosis of the jaw (MRONJ) has become a serious concern for patients under antiresorptive treatment, especially in the oncological setting. Different approaches have been described in the management of MRONJ, including innovative autofluorescence-guided surgery. However, until now,...

Cite
Otto S, Schnödt EM, Haidari S, et al. Autofluorescence-guided surgery for the treatment of medication-related osteonecrosis of the jaw (MRONJ): a retrospective single-center study. Oral Surg Oral Med Oral Pathol Oral Radiol. 2020;131(5):519-526doi: 10.1016/j.oooo.2020.10.018.
Otto, S., Schnödt, E. M., Haidari, S., Brunner, T. F., Aljohani, S., Mosleh, M., Ristow, O., Troeltzsch, M., Pautke, C., Ehrenfeld, M., & Fliefel, R. (2021). Autofluorescence-guided surgery for the treatment of medication-related osteonecrosis of the jaw (MRONJ): a retrospective single-center study. Oral surgery, oral medicine, oral pathology and oral radiology, 131(5), 519-526. https://doi.org/10.1016/j.oooo.2020.10.018
Otto, Sven, et al. "Autofluorescence-guided surgery for the treatment of medication-related osteonecrosis of the jaw (MRONJ): a retrospective single-center study." Oral surgery, oral medicine, oral pathology and oral radiology vol. 131,5 (2021): 519-526. doi: https://doi.org/10.1016/j.oooo.2020.10.018
Otto S, Schnödt EM, Haidari S, Brunner TF, Aljohani S, Mosleh M, Ristow O, Troeltzsch M, Pautke C, Ehrenfeld M, Fliefel R. Autofluorescence-guided surgery for the treatment of medication-related osteonecrosis of the jaw (MRONJ): a retrospective single-center study. Oral Surg Oral Med Oral Pathol Oral Radiol. 2021 May;131(5):519-526. doi: 10.1016/j.oooo.2020.10.018. Epub 2020 Oct 26. PMID: 33309263.
Copy Download .nbib Format: NLM
Use of Bone Resorption Inhibitors in Metastatic Castration-Resistant Prostate Cancer-20 Years Later, and the Answer Is Still Yes.

JAMA network open

Takvorian SU, Haas NB.
PMID: 34292339
JAMA Netw Open. 2021 Jul 01;4(7):e2117159. doi: 10.1001/jamanetworkopen.2021.17159.

No abstract available.

Cite
Takvorian SU, Haas NB. Use of Bone Resorption Inhibitors in Metastatic Castration-Resistant Prostate Cancer-20 Years Later, and the Answer Is Still Yes. JAMA Netw Open. 2021;4(7):e2117159doi: 10.1001/jamanetworkopen.2021.17159.
Takvorian, S. U., & Haas, N. B. (2021). Use of Bone Resorption Inhibitors in Metastatic Castration-Resistant Prostate Cancer-20 Years Later, and the Answer Is Still Yes. JAMA network open, 4(7), e2117159. https://doi.org/10.1001/jamanetworkopen.2021.17159
Takvorian, Samuel U, and Haas, Naomi B. "Use of Bone Resorption Inhibitors in Metastatic Castration-Resistant Prostate Cancer-20 Years Later, and the Answer Is Still Yes." JAMA network open vol. 4,7 (2021): e2117159. doi: https://doi.org/10.1001/jamanetworkopen.2021.17159
Takvorian SU, Haas NB. Use of Bone Resorption Inhibitors in Metastatic Castration-Resistant Prostate Cancer-20 Years Later, and the Answer Is Still Yes. JAMA Netw Open. 2021 Jul 01;4(7):e2117159. doi: 10.1001/jamanetworkopen.2021.17159. PMID: 34292339.
Copy Download .nbib Format: NLM
Cardiovascular Safety of Denosumab Across Multiple Indications.

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research

Shao L, Wu XD, Huang W.
PMID: 33095450
J Bone Miner Res. 2021 Mar;36(3):617-618. doi: 10.1002/jbmr.4189. Epub 2020 Oct 23.

No abstract available.

Cite
Shao L, Wu XD, Huang W. Cardiovascular Safety of Denosumab Across Multiple Indications. J Bone Miner Res. 2020;36(3):617-618doi: 10.1002/jbmr.4189.
Shao, L., Wu, X. D., & Huang, W. (2021). Cardiovascular Safety of Denosumab Across Multiple Indications. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 36(3), 617-618. https://doi.org/10.1002/jbmr.4189
Shao, Long, et al. "Cardiovascular Safety of Denosumab Across Multiple Indications." Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research vol. 36,3 (2021): 617-618. doi: https://doi.org/10.1002/jbmr.4189
Shao L, Wu XD, Huang W. Cardiovascular Safety of Denosumab Across Multiple Indications. J Bone Miner Res. 2021 Mar;36(3):617-618. doi: 10.1002/jbmr.4189. Epub 2020 Oct 23. PMID: 33095450.
Copy Download .nbib Format: NLM
Success Rate and Safety of Dental Implantology in Patients Treated With Antiresorptive Medication: A Systematic Review.

The Journal of oral implantology

Papadakis I, Spanou A, Kalyvas D.
PMID: 32663267
J Oral Implantol. 2021 Apr 01;47(2):169-180. doi: 10.1563/aaid-joi-D-19-00088.

There is no agreement of data on the subject of implant failure and the development of osteonecrosis in patients receiving antiresorptive agents. The purpose of this systematic review is to evaluate whether dental implants placed in patients on antiresorptive...

Cite
Papadakis I, Spanou A, Kalyvas D. Success Rate and Safety of Dental Implantology in Patients Treated With Antiresorptive Medication: A Systematic Review. J Oral Implantol. 2021;47(2):169-180doi: 10.1563/aaid-joi-D-19-00088.
Papadakis, I., Spanou, A., & Kalyvas, D. (2021). Success Rate and Safety of Dental Implantology in Patients Treated With Antiresorptive Medication: A Systematic Review. The Journal of oral implantology, 47(2), 169-180. https://doi.org/10.1563/aaid-joi-D-19-00088
Papadakis, Ioannis, et al. "Success Rate and Safety of Dental Implantology in Patients Treated With Antiresorptive Medication: A Systematic Review." The Journal of oral implantology vol. 47,2 (2021): 169-180. doi: https://doi.org/10.1563/aaid-joi-D-19-00088
Papadakis I, Spanou A, Kalyvas D. Success Rate and Safety of Dental Implantology in Patients Treated With Antiresorptive Medication: A Systematic Review. J Oral Implantol. 2021 Apr 01;47(2):169-180. doi: 10.1563/aaid-joi-D-19-00088. PMID: 32663267.
Copy Download .nbib Format: NLM
Denosumab versus zoledronic acid in cases of surgically unsalvageable giant cell tumor of bone: A randomized clinical trial.

Journal of bone oncology

Li S, Chen P, Yang Q.
PMID: 30740297
J Bone Oncol. 2019 Jan 23;15:100217. doi: 10.1016/j.jbo.2019.100217. eCollection 2019 Apr.

BACKGROUND: Although denosumab has been approved as an antiresorptive agent for giant cell tumor of bone, its efficacy has not been proven.OBJECTIVES: To compare the efficacy and safety of denosumab and zoledronic acid treatment in patients with surgically unsalvageable...

Cite
Li S, Chen P, Yang Q. Denosumab versus zoledronic acid in cases of surgically unsalvageable giant cell tumor of bone: A randomized clinical trial. J Bone Oncol. 2019;15:100217doi: 10.1016/j.jbo.2019.100217.
Li, S., Chen, P., & Yang, Q. (2019). Denosumab versus zoledronic acid in cases of surgically unsalvageable giant cell tumor of bone: A randomized clinical trial. Journal of bone oncology, 15100217. https://doi.org/10.1016/j.jbo.2019.100217
Li, Shenglong, et al. "Denosumab versus zoledronic acid in cases of surgically unsalvageable giant cell tumor of bone: A randomized clinical trial." Journal of bone oncology vol. 15 (2019): 100217. doi: https://doi.org/10.1016/j.jbo.2019.100217
Li S, Chen P, Yang Q. Denosumab versus zoledronic acid in cases of surgically unsalvageable giant cell tumor of bone: A randomized clinical trial. J Bone Oncol. 2019 Jan 23;15:100217. doi: 10.1016/j.jbo.2019.100217. eCollection 2019 Apr. PMID: 30740297; PMCID: PMC6357891.
Copy Download .nbib Format: NLM
Why worry about bisphosphonate-related osteonecrosis of the jaw? A guide to diagnosis, initial management, and referral of patients.

The British journal of general practice : the journal of the Royal College of General Practitioners

Payne KF, Goodson AM, Tahim AS, Rafi I, Brennan PA.
PMID: 28663433
Br J Gen Pract. 2017 Jul;67(660):330-331. doi: 10.3399/bjgp17X691565.

No abstract available.

Cite
Payne KF, Goodson AM, Tahim AS, et al. Why worry about bisphosphonate-related osteonecrosis of the jaw? A guide to diagnosis, initial management, and referral of patients. Br J Gen Pract. 2017;67(660):330-331doi: 10.3399/bjgp17X691565.
Payne, K. F., Goodson, A. M., Tahim, A. S., Rafi, I., & Brennan, P. A. (2017). Why worry about bisphosphonate-related osteonecrosis of the jaw? A guide to diagnosis, initial management, and referral of patients. The British journal of general practice : the journal of the Royal College of General Practitioners, 67(660), 330-331. https://doi.org/10.3399/bjgp17X691565
Payne, Karl Fb, et al. "Why worry about bisphosphonate-related osteonecrosis of the jaw? A guide to diagnosis, initial management, and referral of patients." The British journal of general practice : the journal of the Royal College of General Practitioners vol. 67,660 (2017): 330-331. doi: https://doi.org/10.3399/bjgp17X691565
Payne KF, Goodson AM, Tahim AS, Rafi I, Brennan PA. Why worry about bisphosphonate-related osteonecrosis of the jaw? A guide to diagnosis, initial management, and referral of patients. Br J Gen Pract. 2017 Jul;67(660):330-331. doi: 10.3399/bjgp17X691565. PMID: 28663433; PMCID: PMC5565873.
Copy Download .nbib Format: NLM
Response to the letter to the editor.

Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons

Carlson ER.
PMID: 25109576
J Oral Maxillofac Surg. 2014 Sep;72(9):1641-2. doi: 10.1016/j.joms.2014.05.010.

No abstract available.

Cite
Carlson ER. Response to the letter to the editor. J Oral Maxillofac Surg. 2014;72(9):1641-2doi: 10.1016/j.joms.2014.05.010.
Carlson, E. R. (2014). Response to the letter to the editor. Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons, 72(9), 1641-2. https://doi.org/10.1016/j.joms.2014.05.010
Carlson, Eric R. "Response to the letter to the editor." Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons vol. 72,9 (2014): 1641-2. doi: https://doi.org/10.1016/j.joms.2014.05.010
Carlson ER. Response to the letter to the editor. J Oral Maxillofac Surg. 2014 Sep;72(9):1641-2. doi: 10.1016/j.joms.2014.05.010. PMID: 25109576.
Copy Download .nbib Format: NLM
Re: Management of antiresorptive osteonecrosis of the jaws with primary surgical resection.

Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons

Schwartz HC, O'Ryan FS.
PMID: 25109577
J Oral Maxillofac Surg. 2014 Sep;72(9):1641. doi: 10.1016/j.joms.2014.05.009.

No abstract available.

Cite
Schwartz HC, O'Ryan FS. Re: Management of antiresorptive osteonecrosis of the jaws with primary surgical resection. J Oral Maxillofac Surg. 2014;72(9):1641doi: 10.1016/j.joms.2014.05.009.
Schwartz, H. C., & O'Ryan, F. S. (2014). Re: Management of antiresorptive osteonecrosis of the jaws with primary surgical resection. Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons, 72(9), 1641. https://doi.org/10.1016/j.joms.2014.05.009
Schwartz, Harry C, and O'Ryan, Felice S. "Re: Management of antiresorptive osteonecrosis of the jaws with primary surgical resection." Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons vol. 72,9 (2014): 1641. doi: https://doi.org/10.1016/j.joms.2014.05.009
Schwartz HC, O'Ryan FS. Re: Management of antiresorptive osteonecrosis of the jaws with primary surgical resection. J Oral Maxillofac Surg. 2014 Sep;72(9):1641. doi: 10.1016/j.joms.2014.05.009. PMID: 25109577.
Copy Download .nbib Format: NLM
Prevalence of osteoporosis in the ESOSVAL cohort: reply to the comment by Pedrera-Zamorano et al.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA

Sanfélix-Genovés J, Hurtado I, Sanfélix-Gimeno G, Peiró S.
PMID: 23052932
Osteoporos Int. 2013 Jun;24(6):1925-6. doi: 10.1007/s00198-012-2146-z. Epub 2012 Sep 29.

No abstract available.

Cite
Sanfélix-Genovés J, Hurtado I, Sanfélix-Gimeno G, et al. Prevalence of osteoporosis in the ESOSVAL cohort: reply to the comment by Pedrera-Zamorano et al. Osteoporos Int. 2012;24(6):1925-6doi: 10.1007/s00198-012-2146-z.
Sanfélix-Genovés, J., Hurtado, I., Sanfélix-Gimeno, G., & Peiró, S. (2013). Prevalence of osteoporosis in the ESOSVAL cohort: reply to the comment by Pedrera-Zamorano et al. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 24(6), 1925-6. https://doi.org/10.1007/s00198-012-2146-z
Sanfélix-Genovés, J, et al. "Prevalence of osteoporosis in the ESOSVAL cohort: reply to the comment by Pedrera-Zamorano et al." Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA vol. 24,6 (2013): 1925-6. doi: https://doi.org/10.1007/s00198-012-2146-z
Sanfélix-Genovés J, Hurtado I, Sanfélix-Gimeno G, Peiró S. Prevalence of osteoporosis in the ESOSVAL cohort: reply to the comment by Pedrera-Zamorano et al. Osteoporos Int. 2013 Jun;24(6):1925-6. doi: 10.1007/s00198-012-2146-z. Epub 2012 Sep 29. PMID: 23052932.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 36 entries